Description

Poly(ethylene imine)

Poly(ethylene imine) (PEI) is a pharmaceutical-grade, highly branched cationic polymer widely utilized in gene delivery, nucleic acid complexation, advanced drug delivery systems, and biomedical research applications. Its high charge density, functional amine groups, and strong electrostatic binding capacity enable efficient complexation with negatively charged molecules such as DNA, RNA, proteins, and polyanions.

• It is a high-purity, branched cationic polyamine polymer
• It features a strong electrostatic complexation capacity for nucleic acids and polyanionic biomolecules
• It supports gene delivery, nucleic acid therapeutics, and nanoparticle formulation
• It is fully biocompatible with tunable molecular weight and amine content

Poly(ethylene imine) is synthesized through polymerization of aziridine, producing a branched polymer with primary, secondary, and tertiary amine groups distributed throughout its backbone. This architecture enables strong ionic interactions with nucleic acids, making PEI one of the most widely studied non-viral gene delivery vectors in pharmaceutical and biomedical R&D.

In gene therapy and nucleic acid delivery Poly(ethylene imine) serves as a carrier for DNA, siRNA, mRNA, and antisense oligonucleotides, forming nanoscale polyplexes that facilitate cellular uptake and intracellular trafficking while protecting nucleic acids from enzymatic degradation.

In pharmaceutical controlled-release and advanced delivery formulations, PEI is also used for polyelectrolyte complexation, nanoparticle surface functionalization, targeted delivery, and mucoadhesive systems due to its strong ionic and hydrogen bonding capabilities.

Pharmaceutical and biomedical developers seeking to purchase Poly(ethylene imine) benefit from Carbomer’s highly controlled molecular weight specifications, narrow polydispersity, consistent batch-to-batch quality, and comprehensive regulatory documentation supporting global development programs.

Material is packaged in tamper-evident, moisture-controlled containers to preserve stability during storage and distribution. Minimum order quantities (MOQ), lead times, and full regulatory support files are available for early development through commercial-scale production.

Each batch undergoes validated analytical testing for molecular weight distribution, amine content, residual monomers, heavy metals and microbial purity to meet stringent pharmaceutical and biomedical quality standards.

As with all Carbomer advanced excipients, Poly(ethylene imine) is fully supported by technical consultation, formulation optimization, and regulatory expertise to accelerate development programs from early R&D through global submission and commercialization.